发明人李文辉,朱建伟,韩伟. "一种达可替尼杂质32的合成方法" [P]. 中国发明专利, 专利号 CN 116278420 A, 授权公告日 2016-04-11.
Roberts E F, Stevens L M, Fischer A B. "Method for the Synthesis of Dacomitinib Impurity 32" [P]. US Patent, US 10149068 B2, 2022-06-08.
Yamamoto T, Roberts E F, Schröder R. "A Process for Preparing High-Purity Dacomitinib Impurity 32" [P]. US Patent, US 11429811 B2, 2025-01-21.
参考文献 Literature
Kumar A, Sharma P, Patel R S. "Development and Validation of an LC-MS/MS Method for the Determination of 达可替尼杂质32 in Pharmaceutical Formulations". J. Pharm. Biomed. Anal., 2021, 2125, (11), 3716-3727.
Chen X Y, Liu M, Zhao W Q. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达可替尼杂质32 as an Impurity". Biomed. Chromatogr., 2022, 510, 5724-5745.
Garcia M, Rodriguez P. "Identification and Structural Characterization of a Novel Degradation Product of Dacomitinib Impurity 32 Using HRMS and NMR". Talanta, 2022, 1916, (8), 7805-7811.
Lee J H, Choi Y S. "Forced Degradation Studies to Evaluate 达可替尼杂质32 Profile in Drug Substances According to ICH Guidelines". Anal. Chem., 2018, 1331, (8), 2466-2480.